… /TAZO in critically ill obese patients immediately after the first administered dose. In the context
of … maximization of PIP/TAZO dose at baseline to rapidly saturate increased V d in obese …

… Piperacillin/tazobactam or piperacillin were prescribed according to local protocol, in
most cases at 75/9.375 or 75 mg.kg −1 , respectively. Antibiotic agents were administered by …

… for morbidly obese individuals. The peculiar interactions of several antibiotics are affected by
morbid obesity (… in normal renal functioning morbidly obese patients were developed. It was …

… intermittent infusion piperacillin/tazobactam or meropenem in critically ill patients with sepsis;
… piperacillin/tazobactam regimens do not consistently achieve goal PTA at an MIC of 16 mg/…

… dosing in HFIM, piperacillin/tazobactam and meropenem stock solutions were prepared from
piperacillin/tazobactam (… ) and meropenem (Meropenem, 1000 mg, Fresenius Kabi Pty Ltd, …

… were admitted to the intensive care unit (ICU), of which 179 patients received empirical
piperacillin/tazobactam treatment and were included. Moreover, in total, 335 piperacillin …

… Patients were included only if: the first piperacillin–tazobactam dose was administered in the
… of the therapy was at least 48 h, and the patient was not admitted to the intensive care unit. …

… -based dose optimisation of piperacillin/tazobactam to improve outcome in patients with
sepsis (… on CRRT, and those on ECMO and/or morbid obesity. Prospective studies focusing on …

… Piperacillin/tazobactam (TZP) is the only commercially … dosing is recommended in the
package insert, a dosing strategy … in critically ill patients when targeting an MIC of 16 mg/L [20]. …

… Numerous studies have suggested that the combination of piperacillin-tazobactam (… patients
receiving combination PT and vancomycin developed AKI, compared with 12.9% of patients …